Prescription Drug Affordability Review Board

Colorado Prescription Drug Affordability Review Board & Advisory Council

Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.

PDAB Members

Dr. Sami Diab, MD of Greenwood Village, Colorado
Dr. Amy Gutierrez, PharmD of Aurora, Colorado
Catherine Harshbarger, RN, MHA of Holyoke, Colorado
Board Chair, Dr. Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado
Dr. James Justin VandenBerg, PharmD, BCPS of Denver, Colorado

PDAAC Members

Kim Bimestefer, Executive Director of HCPF
Gail DeVore, representing health care consumers
Sarita Parikh, representing health care consumers
Dr. Bob Mulch, representing statewide health care advocacy organizations
PDAAC Chair, Dr. Kimberley Jackson, representing health care consumers living with chronic conditions
Open position representing labor unions
PDAAC Vice Chair, Nathan Wilkes, representing employers
Open position representing carriers
Marc Reese, representing PBMs
Dr. Richard Miranda, representing health care professionals with prescribing authority
Dr. Brett McQueen, representing research organizations
Katelin Lucariello, representing brand name manufacturers
Fayez Azeez, representing generic manufacturers
Dr. Ingrid Pan, representing pharmacists
Leah Lindahl, representing wholesalers

Conflicts of Interest

PDAB Conflict of Interest Policy and Procedure

PDAB Conflict of Interest Disclosure

PDAAC Conflict of Interest Policy and Procedure

PDAAC Conflict of Interest Disclosure

Announcements

To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
The Board will hold its third rulemaking hearing for Enbrel's upper payment limit on August 22, 2025. Link to register for the meeting can be found below.
The Board has completed its 2024 Activities Summary Report. The report can be found under the Public Resources section of the website.
The data submission guide (DSG) is available for public use. The DSG provides guidance for stakeholders that are interested in submitting information for the Board's consideration during the rulemaking hearing for Enbrel's upper payment limit (UPL). The DSG also includes details on how to submit confidential information.
PDAAC is currently recruiting new council members to represent labor unions, carriers, and health care consumers. If you are interested in serving a 3-year term on the PDAAC, please fill out the linked application.

PDAB Meetings

The next PDAB meeting will be held on Friday, August 22, 2025 from 10 am - 1 pm MT.

Note: previous meeting materials can be accessed by emailing dora_ins_pdab@state.co.us.

2025 PDAB/PDAAC Meeting Links & Recordings
August 22 Meeting Agenda: coming soon
DRAFT Cosentyx Addendum
DRAFT Stelara Addendum
Draft Proposed UPL Rule for Enbrel

PDAAC Meetings

The next PDAAC meeting will be held on Thursday, August 28 2025 from 9 - 11 am MT.

PDAAC Meeting Materials Note: earlier meeting materials can be accessed by emailing dora_ins_pdab@state.co.us.
Adopted Policies

Office Hours

Office hours are an informal space for stakeholders to ask questions about PDAB processes and to provide resources for stakeholders to testify during rulemaking hearings. Office hours are currently on hold. For any questions or to provide resources, please email dora_ins_pdab@state.co.us.

PDAB Rulemaking

The UPL rulemaking for Enbrel began during the May 23 PDAB meeting. The second Enbrel UPL rulemaking hearing was on July 11 and the third rulemaking hearing will be on August 22. The Board anticipates holding at least 3 rulemaking hearings for each drug. For more information on PDAB rulemaking and how to provide testimony during a PDAB rulemaking hearing, please visit the linked PDAB Rulemaking Guide. Following are the documents related to Enbrel's UPL rulemaking hearing.

Providing Public Comment

The PDAB welcomes general public comments during PDAB meetings. Comments are limited to 2 minutes per person. Public comment is not a time for the Board to interact with the public.

Verbal Public Comment: To provide verbal comments, please fill out the sign up form that will be provided at each meeting. Public comments will be limited to 2 minutes per person.
Written Public Comment: To provide written comments about general PDAB business or agenda items, please email dora_ins_pdab@state.co.us. Written comments will be accepted up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.

Providing Testimony

Verbal or written testimony occurs only during PDAB rulemaking hearings and will be included in the rulemaking record. The Board may ask questions of stakeholders during their testimony. Visit the PDAB Rulemaking Guide for more information on testifying at a PDAB rulemaking hearing.

Verbal Testimony: To provide verbal testimony, please fill out the testimony sign up form. Verbal testimony may be limited in duration.
Written Testimony: please submit written testimony via dora_ins_pdab@state.co.us. Written testimonies will be accepted up to 48 hours before each rulemaking hearing. Comments submitted after the 48-hour deadline will be considered for the following rulemaking hearing.